ArticleJAMA network open2022
Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use.
Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 55 citations in OpenAlex.
- HIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons.Emerging infectious diseases · 2024Trial
- Utilizing Machine Learning for Predicting PrEP Use Status Among Sexual and Gender Minority Young Adults.Prevention science : the official journal of the Society for Prevention Research · 2026Article
- Modelling the 5-Year Impact of Twice-Yearly Injectable Lenacapavir for HIV Pre-Exposure Prophylaxis in the United States.Journal of the International AIDS Society · 2026Article
- Methamphetamine Use and HIV Risk Behaviors in a Cohort of Homeless-Experienced Adults Who Use Drugs.AIDS and behavior · 2026Article
- HIV Pre-Exposure Prophylaxis Service Cascade and Risk Factors Associated with Loss to Follow-Up Among Key Populations in Indonesia: Data from a Real-World Pilot Implementation 2021-2023.AIDS and behavior · 2026Article
- Pre-exposure prophylaxis (PrEP) and medications for opioid use disorder for persons who inject drugs: the CHORUS + randomized controlled trial study protocol.Addiction science & clinical practice · 2025Article
- HIV Diagnosis and Preexposure Prophylaxis (PrEP) Prescription Among Commercially Insured Persons With Bipolar Disorder.The Journal of clinical psychiatry · 2025Article
- "The Simplest Way to Go": An Exploration of Why Women Who Inject Drugs Chose Long-Acting Injectable Cabotegravir Instead of Daily Oral PrEP.AIDS and behavior · 2025Article
- Changes in the PrEP Care Cascade in People Who Inject Drugs in 2018 and 2022.AIDS and behavior · 2025Article
- Preferences for Pre-Exposure Prophylaxis Implementation and Engagement in the HIV Pre-Exposure Prophylaxis Care Continuum Among Patients Receiving Psychiatric Care in an Ending the HIV Epidemic Priority County.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Substance Checking Outreach and PrEP Engagement (SCOPE) Study: protocol for a non-randomised clinical trialBMJ open · 2025Article
- U.S. substance use harm reduction efforts: a review of the current state of policy, policy barriers, and recommendations.Harm reduction journal · 2025Review
- Oral pre-exposure prophylaxis (PrEP) receipt and persistence among opioid-dependent people who inject drugs initiating PrEP for HIV prevention.Journal of substance use and addiction treatment · 2025Article
- Assessing inequities in buprenorphine treatment across the care cascade.Drug and alcohol dependence · 2025Observational
- Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Perceptions of People Who Inject Drugs About Long-acting Medications for Opioid Use Disorder, Preexposure Prophylaxis, and Antiretroviral Therapy.Open forum infectious diseases · 2025Article
- Association between homelessness and PrEP uptake among men who have sex with men: Results from the American Men's Internet Survey, 2017-2021.Social science & medicine (1982) · 2025Article
- HIV and HCV Screening, and Pre-Exposure Prophylaxis Among Managed Care Beneficiaries with Substance Use Disorders: A Cross-Sectional Study from a Single State.Risk management and healthcare policy · 2025Article
- Article
- HIV incidence and recreational drug use among men who have sex with men aged 18-24 years in Tianjin, China: a retrospective cohort study.BMC infectious diseases · 2024Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Importance: Although HIV preexposure prophylaxis (PrEP) implementation among persons who inject drugs has been inadequate, national HIV monitoring programs do not include data on PrEP, and specific trends in PrEP use are not well understood. Objective: To estimate HIV PrEP uptake among commercially insured persons with opioid or stimulant use disorder by injection drug use (IDU) status. Design, Setting, and Participants: This cross-sectional study used deidentified data from the MarketScan Commercial Claims and Encounters Database to identify a sample of 547 709 commercially insured persons without HIV but with opioid and/or stimulant use disorder, including 110 592 with evidence of IDU between January 1, 2010, and December 31, 2019. Data were analyzed from November 1, 2020, to July 1, 2021. Exposures: Persons with opioid and/or stimulant use disorder and evidence of IDU were identified through claims data. Main Outcomes and Measures: The outcome was receipt of tenofovir disoproxil fumarate and emtricitabine for PrEP as identified from filled pharmacy claims. Multivariable logistic regression was used to assess the association of demographic and clinical characteristics with receipt of PrEP. Results: The study cohort included 211 609 (28.6%) females and 336 100 (61.4%) males with a combined mean (SD) age of 34.8 (13.1) years, including 110 592 individuals with evidence of IDU. During the study period, 508 (0.09%) persons with opioid and/or stimulant use disorder, including 170 (0.15%) with evidence of IDU, received PrEP. Receipt of PrEP increased from 0.001 to 0.243 per 100 person-years from 2010 through 2019 among the entire cohort and from 0.000 to 0.295 per 100 person-years among those with IDU. In multivariable analysis, PrEP use was more likely among males (adjusted odds ratio [aOR] 8.72; 95% CI, 6.39-11.89), persons with evidence of IDU (aOR, 1.47; 95% CI, 1.21-1.79), and persons with evidence of sexual risk indications for PrEP (aOR, 23.68; 95% CI, 19.57-28.66). Conclusions and Relevance: In this cross-sectional study of commercially insured persons with opioid and/or stimulant use disorder, HIV PrEP delivery remained low, including among those with evidence of IDU. PrEP should be consistently offered alongside substance use disorder treatment and other harm reduction and HIV prevention services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.